New Data from EMA’s Review of Medicines with Pseudoephedrine
Pseudoephedrine is an oral treatment that can be used alone or in combination with other medicines to treat nasal congestion resulting from a cold, flu, or allergy.
The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) has begun their review, as of Feb. 10, 2023, of medicines containing pseudoephedrine following concerns about the risk of posterior reversible encephalopathy syndrome (PRES) and reversible cerebral vasoconstriction syndrome (RCVS), which are conditions affecting blood vessels in the brain.
PRES and RCVS can lead to reduced blood supply, or ischemia, to the brain and may lead to major and life-threatening complications in some cases. Some of the most common symptoms associated with these conditions include headache, nausea, and seizures.
Pseudoephedrine is an oral treatment that can be used alone or in combination with other medicines to treat nasal congestion resulting from a cold, flu, or allergy. Most pseudoephedrine-containing medicines have a known risk of cardiovascular and cerebrovascular ischemic events, such as stroke or heart attack.
The recent review follows new data from a small number of cases of PRES and RCVS in patients using pseudoephedrine-containing medicines, which were reported in pharmacovigilance databases and the medical literature.
The PRAC will continue to review available evidence and make decisions on whether the marketing authorizations for pseudoephedrine-containing medicines should be maintained, varied, suspended, or withdrawn across the EU.
Source: European Medicines Agency
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
